Loading...
The impact of TRIPS on innovation and exports
Malhotra, Prabodh
Malhotra, Prabodh
Author(s)
Contributor(s)
Keywords
GE Subjects
Collections
Files
Loading...
getpdf_3.pdf
Adobe PDF, 77.7 KB
Research Projects
Organizational Units
Journal Issue
Online Access
Abstract
Currently, there is a debate on what impact the implementation of the Trade Related Aspects of Intellectual Property Rights (TRIPS) in India would have on its pharmaceutical industry and health care. The debate hinges primarily on two major questions. First, will the new patent regime provide an impetus for innovation in the pharmaceutical industry? Second, how far will India’s pharmaceutical exports of copied versions of patented drugs to developing countries be restricted under the new regime? The first question seeks to find out if TRIPS will increase India’s innovative capabilities to fill the current vacuum to develop drugs for tropical diseases. The large multinational companies (MNCs) that dominate the global pharmaceutical industry have no interest in commercial ventures that have little potential for great returns on investment. The second question attempts to find a solution to the lack of access to medicine in most developing countries. Indian manufacturers’ supply of reverse-engineered drugs, which cost only a fraction of the prices charged by MNCs, may be coming to an end under the new regime. Against this backdrop, this article attempts to analyse the impact of strengthening intellectual property rights in India.
Note(s)
Topic
Type
Article
Date
2008-04
Identifier
ISBN
DOI
Copyright/License
With permission of the license/copyright holder